Fagron versnelt globale expansie met twee strategische overnames en verkrijgt belangrijke licentie in Noord Amerika Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 19 december 2025 – 7:00 AM CET Fagron versnelt globale expansie met twee strategische overnames en verkrijgt belangrijke licentie in Noord Amerika Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, is verheugd om twee strategische overnames aan te kondigen. Deze overnames helpen om onze globale aanwezigheid verder te versterken en capaciteiten te diversifiëren...
Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2025 – 7:00 AM CET Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone Fagron, the leading global player in pharmaceutical compounding, is pleased to announce two strategic acquisitions that further strengthen its global footprint and diversify its capabilities. These transactions include Amber Compounding Pharmacy, a...
Sequana announces granting of a key additional methods and formulation patent for DSR. This patent increases durability and expands protection of Sequana's DSR IP, thereby improving its value. We note that the patent provides additional time for Sequana to secure dedicated financing to advance DSR toward the randomized controlled portion of the MOJAVE clinical study. We reiterate our BUY rating.
How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...
Shurgard acquired two Sesam Self Storage facilities in Lund and Helsingborg, Sweden, from Granitor. The deal closed on 2/12/25, adding 11,200 sqm of space across 1,800 units. The occupancy currently stands at approx. 20%. Both freehold properties will be remotely managed from existing Shurgard sites as part of its cluster strategy. This was illustrated in our recent property tour and reduces the headcount per store. It also brings more FTE together in 1 location which increases the job satisfact...
Colruyt: Only 5 stores left to divest in France. EVS: Lower end of the range becomes the base case, on longer lead times. Fagron: Two EMEA acquisitions and California license for FSS. Kinepolis: “Wicked” achieves solid box office. OCI: Divesting Rotterdam ammonia terminal for €290m. Prosus: 1HFY26 results – on track
Sequana reported the first US commercial alfapump implant at Mount Sinai Hospital in New York. This important milestone shows the demand for the alfapump in the US. We adjust our TP from € 2.8 to € 2.7 to reflect the new share count and reiterate our BUY rating.
Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 24 November 2025 – 7:00 AM CET Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business Fagron, the global leader in pharmaceutical compounding, has reinforced its EMEA position with the acquisitions of a book of business from Amara (Poland) and Magilab (Hungary). These deals support F...
Fagron versterkt leiderschap in de EMEA-regio met overnames in Polen en Hongarije en kondigt belangrijke ontwikkelingen aan voor de Noord-Amerikaanse activiteiten Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 24 November 2025 – 07.00 uur CET Fagron versterkt leiderschap in de EMEA-regio met overnames in Polen en Hongarije en kondigt belangrijke ontwikkelingen aan voor de Noord-Amerikaanse activiteiten Fagron, wereldwijd marktleider in farmaceutische bereidingen, heeft zijn positie in de EMEA-regio versterkt door de overname van een klantenportefeuille va...
Fagron completes share buy-back program Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 November 2025 – 6PM CET Fagron completes share buy-back program In the period from 10 November 2025 through 14 November 2025, Fagron purchased 44,000 of its owns shares at an average price of €20.7208 per share corresponding to a total amount of €911,717.00. A total of 200,000 Fagron shares have been repurchased under the buy-back program at an average price of € 20.6805 per share, corresponding to a total amount of € 4,136,093.00. The share buy-back program was announced on ...
Voortgang aandeleninkoopprogramma Fagron Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 14 november 2025 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode van 10 november 2025 tot en met 14 november 2025 heeft Fagron 44.000 eigen aandelen ingekocht voor een gemiddelde prijs van € 20,7208 per aandeel wat overeenkomt met een totaalbedrag van € 911.717,00. Het totaal van 200.000 Fagron aandelen is aangekocht tegen een gemiddelde koers van € 20,6805 per aandeel, wat overeenkomt met een totaalbedrag van € 4.136.093,00. Het aandeleninkoopprogramma was aan...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.